Seroquel XR in the Long Term Treatment of Schizophrenia

N/ACompletedNCT01202617

AstraZeneca1,606 enrolled

Overview

The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improves the relapse prevention in schizophrenic outpatients

Study Type

OBSERVATIONAL

Enrollment

1,606

Conditions

Relapse in Schizophrenia

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * schizophrenic outpatients on at least 600 mg Seroquel XR treatment for at least 1 month Exclusion Criteria: * Severe cerebro- and cardiovascular disease, severe hepatic impairment, gravidity

Locations (61)

Outcomes

Primary Outcomes

Rate of patients remained relapse free after 6 months of treatment

Time frame: on the 60th day of treatment

Rate of patients remained relapse free after 6 months of treatment

Time frame: on the 180th day of treatment

Secondary Outcomes

connection between relapse and affective symptoms

Time frame: on the 60th day of treatment

connection between relapse and affective symptoms

Time frame: 180th day of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Research Site

Baja, Hungary

Research Site

Balassagyarmat, Hungary

Research Site

Barcs, Hungary

Research Site

Berettyóújfalu, Hungary

Research Site

Budapest, Hungary

Research Site

Cegléd, Hungary

Research Site

Csongrád, Hungary

Research Site

Debrecen, Hungary

Research Site

Dombóvár, Hungary

Research Site

Dunaújváros, Hungary

...and 51 more locations